Related Experiment Video
Updated: Aug 27, 2026

Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Periodontitis and metabolic dysfunction-associated steatotic liver disease
Rafael Scaf de Molon1, Erica Dorigatti de Avila1, Davi da Silva Barbirato2,3
1Department of Diagnosis and Surgery, São Paulo State University, School of Dentistry, Aracatuba, Brazil.
Objective:
Periodontitis is a chronic inflammatory disease with systemic effects that extend beyond the oral cavity and contribute to systemic immune and metabolic dysregulation. Chronic liver diseases, particularly metabolic dysfunction-associated steatotic liver disease (MASLD) and its progressive phenotypes, have emerged as major global health challenges. Increasing evidence suggests that these two conditions could be biologically and clinically interconnected, yet their relationship has not been comprehensively analyzed. This review critically appraises and integrates clinical, translational, and experimental evidence linking periodontitis and liver disease, with a particular focus on MASLD and related outcomes.
Materials And Methods:
A comprehensive narrative review of the literature was conducted to synthesize evidence from epidemiological, clinical, translational, genetic, microbiological, and experimental studies investigating the relationship between periodontitis and chronic liver disease. Particular attention was given to studies examining the oral-gut-liver axis, shared immunometabolic mechanisms, and the effects of periodontal therapy on liver-related outcomes.
Results:
Epidemiological studies consistently demonstrate a higher prevalence and severity of periodontitis among individuals with chronic liver disease. Population-based and longitudinal studies further support bidirectional associations between periodontal inflammation and hepatic steatosis, fibrosis, cirrhosis, and liver-related mortality. Interventional studies provide preliminary evidence that periodontal therapy may improve hepatic biochemical, imaging, and inflammatory parameters. Genetic and Mendelian randomization studies indicate partially shared genetic susceptibility and overlapping immunometabolic pathways. Clinical microbiological and experimental studies demonstrate that periodontal dysbiosis, microbial translocation, systemic inflammation, and alterations in gut barrier integrity contribute to hepatic immune activation, oxidative stress, and fibrogenesis, supporting the biological plausibility of an oral-gut-liver axis. Conversely, liver disease-associated metabolic and immune dysfunction may further aggravate periodontal tissue destruction.
Conclusions:
Current evidence supports a biologically plausible bidirectional relationship between periodontitis and chronic liver disease, particularly MASLD. Integration of epidemiological observations with mechanistic findings suggests that periodontal inflammation may contribute to liver disease progression through interconnected microbial, inflammatory, immunological, and metabolic pathways. Although causality remains to be established, these findings support greater integration of periodontal care into the multidisciplinary management of chronic liver disease and highlight the need for well-designed prospective studies and interventional trials to clarify causal mechanisms and therapeutic implications.
Clinical Relevance:
The emerging evidence linking periodontitis and chronic liver disease has important implications for clinical practice and interdisciplinary care. Given the high global prevalence of both conditions and their shared inflammatory and metabolic underpinnings, periodontal inflammation should be considered a clinically relevant comorbidity in patients with steatotic liver disease and other chronic hepatic disorders. Individuals with severe or treatment-refractory periodontitis may benefit from assessment of hepatic metabolic risk, fostering bidirectional collaboration between dental and medical professionals. Incorporating oral health into liver disease management strategies may represent a low-risk, cost-effective adjunct to existing therapies, with the potential to mitigate systemic inflammatory burden and improve long-term outcomes. Ultimately, translating this growing body of knowledge into integrated preventive and therapeutic strategies holds promise for meaningfully improving disease control, quality of life, and overall health outcomes in patients living with MASLD and periodontitis.
Related Concept Videos
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Chronic Pancreatitis II: Pathophysiology
Cirrhosis II: Pathophysiology
Chronic Pancreatitis I: Introduction
Pancreatitis is the inflammation of the pancreas, which occurs when the immune system becomes active and causes swelling, pain, and disruptions in organ function. Pancreatitis can manifest as either an acute or chronic condition.
Acute pancreatitis arises suddenly and lasts for a brief duration, while chronic pancreatitis is a long-term affliction...
Chronic Pancreatitis I: Introduction
Overview of Carbohydrate Metabolism
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...

